GSK Secures February 2026 BLA Approval Letter for SHINGRIX Following Label Update

A February 13, 2026 approval letter from FDA marks the latest regulatory action on GlaxoSmithKline Biologicals' SHINGRIX (Zoster Vaccine Recombinant, Adjuvanted), adding to a compliance record that now spans nine discrete BLA actions since the product's original licensure in October 2017. For biologics manufacturing and QA leads managing post-approval change control under 21 CFR Part 601, each successive approval letter carries updated labeling obligations that must be reconciled against current batch release procedures and promotional materials.

SHINGRIX holds indication for prevention of herpes zoster in adults aged 50 years and older, and in adults aged 18 years and older who are or will be at increased risk due to immunodeficiency or immunosuppression caused by known disease or therapy. The dual-population indication, established progressively through supplemental BLA submissions, means that any label revision requires careful review across both patient-population sections of the package insert before site-level SOPs and labeling specifications are updated.

The February 2026 action follows approval letters issued in July 2025 and March 2025, a cadence that signals active lifecycle management of the BLA rather than a static post-approval posture. For regulatory affairs leads, three approval letters within a twelve-month window represents a meaningful documentation burden: each letter must be assessed for manufacturing-relevant changes, including any revised storage conditions, container-closure specifications, or post-market commitments that flow down to the quality management system under ICH Q10 principles.

GlaxoSmithKline Biologicals, S.A. holds the BLA under STN 125614. Supporting documentation on the FDA product page includes the current package insert, a toxicology review, a clinical review memorandum, and a statistical review and evaluation, resources that QA and regulatory teams should cross-reference when assessing the scope of the February 2026 changes against prior approved labeling versions.

The full approval history, now extending across eight years and multiple supplemental submissions, will serve as a reference baseline when FDA inspectors assess change control documentation and post-approval reporting compliance at GSK's biologics manufacturing sites.

Source: FDA Vaccines, Blood and Biologics product page (STN 125614) via FDA.gov RSS Feed, June 24, 2026.